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Objective: To examine the effect of 109 days of caprylic triglyceride (CT) in a 70-year-old
male with mild Alzheimer’s disease (AD).
Background: Cerebral metabolism is limited to glucose under most conditions, and dimin-
ished cerebral glucose metabolism is a characteristic feature of AD. Another substrate
available for cerebral metabolism is ketone bodies. Ketone bodies (KB) are normally derived
from fat stores under conditions of low glucose availability as an alternative energy sub-
strate to glucose. KB can also be produced by oral administration of CT. Prior studies
suggest that the alternative energy source of CT may improve cognitive function due to
mild to moderate AD, by circumventing the diminished glucose metabolism.
Method: The effect of CT was analyzed in a single-case of mild AD with cognitive alter-
ations in an open label study. Study outcomes included the Montreal cognitive assess-
ment (MoCA), mini mental state exam (MMSE), and 18-fluorodeoxyglucose (18F) positron
emission tomography (FDG PET) scans.
Results: After 109 days of CT, MoCA scores changed from a baseline value of 24–28, and
MMSE scores changed from 23 to 28. No changes were observed on FDG PET scans.
Conclusion: The results suggest that, in a case of mild AD, CT may have affected cog-
nitive function, assessed by means of MMSE and MoCA, although glucose uptake and
metabolism remained unchanged.
Keywords: Alzheimer’s disease, ketone bodies, glucose, apolipoprotein E, Montreal cognitive assessment, mini
mental state exam
INTRODUCTION
THERAPEUTIC RATIONALE
Alzheimer’s disease (AD) is progressive, neurodegenerative disease
characterized by a decline in cognitive abilities. The pathological
hallmarks of AD include accumulation of senile plaques and neu-
rofibrillary tangles in the brain. Variants in three genes, the two
presenilin genes (PSEN1/2) and the amyloid precursor protein
(APP) are known to cause early-onset forms of AD. Amino acid
changes encoded by the gene variants in the APP and PSEN1/2
genes ultimately lead to the accumulation of amyloid beta and
phosphorylated tau and the insidious early-onset of the disease.
These findings, combined with the pathology, strongly implicate
dysregulation in the processing of the APP protein as a central
player in the disease (Schellenberg and Montine, 2012). However,
the majority of patients with AD do not carry disease causing vari-
ants in APP, PSEN1, or PSEN2. Instead, the major risk factors for
sporadic AD are increasing age and the possession of the epsilon
4 (E4) variant of the apolipoprotein E (APOE) gene (Padilla and
Isaacson, 2011).
The brain is one of the most metabolically active organs in the
body, and under most conditions, relies almost exclusively on glu-
cose for its energy needs. Using 18F-2-deoxy-2-fluoro-d-glucose
(18FDG), a positron emitting tracer, the cerebral metabolic rate of
glucose (CMRglc) can be measured. 18-Fluorodeoxyglucose (18F)
positron emission tomography (FDG PET) studies in the early
1980s compared AD subjects with normal controls and found
significant diminished cerebral glucose metabolism (DCGM) in
AD patients. In these studies, significant correlations were found
between DCGM and worsening performance on measures of cog-
nitive function (de Leon et al., 1983). Subsequent studies have
revealed that DCGM in AD is not simply a global decrease
in glucose use across the brain, but rather maps to specific
regions found in the posterior cingulate and parietal, tempo-
ral, and prefrontal cortices. Longitudinal studies have demon-
strated the progression of DCGM over the course of AD. DCGM
can be observed in preclinical AD and progressively worsens as
patients proceed from mild cognitive impairment (MCI) to AD
(Mosconi et al., 2009).
Given the realization that AD begins decades before onset of
clinical signs of dementia, it is important to investigate and develop
low risk interventions that can intervene early in the course of
cognitive decline. One low risk attempt to address the DCGM
in AD is to induce ketosis. Ketosis is the elevation of circulating
ketone bodies, namely beta-hydroxybutyrate (BHB), acetoacetate,
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and acetone. Ketone bodies (KB) are normally produced from the
incomplete oxidation of fatty acids under conditions of low glu-
cose availability and are readily metabolized by the brain to serve as
an alternative to glucose (Owen et al., 1967). Ketosis has tradition-
ally been induced by adherence to a ketogenic diet. Ketogenic diets
were developed to mimic fasting, and have been used for decades
to reduce seizure frequency in pediatric epilepsy (Freeman et al.,
2006).
Ketogenic diets require strict compliance to low carbohydrate
and low protein intake and long term adherence is challenging
even in the best of situations. It is possible to induce ketosis with-
out dietary modification with special fats called medium chain
triglycerides (MCTs). Reger et al. (2004) studied the effects of a
specific MCT called caprylic triglyceride (CT) to induce ketosis
in 20 mild to moderate probable AD subjects [mean age 74.7;
mean mini mental state exam (MMSE) score 22.0]. This study
used a crossover design to examine the effects of acute eleva-
tion of serum KB levels on cognitive performance. A single 40 g
dose of CT induced mild ketosis and a significant positive correla-
tion between performance on the paragraph recall task and serum
BHB concentration was found. In addition, significant improve-
ment was demonstrated in the Alzheimer’s disease assessment
scale-cognitive subscale (ADAS-Cog) scores in subjects who were
non-carriers of APOE4 [APOE4(−)] compared to those who were
carriers [APOE4(+)].
In a follow-up study, Henderson et al. (2009) induced ketosis
in mild to moderate AD subjects (mean MMSE of 23) by daily
dosing of 20 g of CT for 90 days. This study was a randomized,
double-blind, placebo-controlled, multicenter trial conducted at
23 clinical sites within the United States. Consistent with the
earlier acute dosing study, subjects who were APOE4(−) demon-
strated a significant change in ADAS-Cog scores compared to
placebo at both days 45 and 90. As with the earlier study, post-
dose serum BHB levels correlated with improvement in ADAS-Cog
scores, suggesting the induction of ketosis may be beneficial to AD
patients, particularly if they lack an APOE4 allele.
CASE REPORT
Here, we report a case study of a 70-year-old male diagnosed with
probable AD on August 31st, 2012 based on neuropsychiatric test-
ing, MRI and FDG PET findings. The clinical manifestations of
AD were predominately short term memory deficits and process-
ing difficulties, and no affective changes or behavioral issues were
present. His physical exam was non-diagnostic, and laboratory
studies were all normal, including a thyroid panel and B12 level.
He is a retired executive, has a generally benign past medical his-
tory, was taking no medications at the time of his presentation,
and exercised and golfed regularly.
The patient was evaluated by Montreal cognitive assessment
(MoCA), MMSE, and FDG PET scans on the day of diagnosis.
The MoCA is a rapid screening instrument for cognitive dysfunc-
tion. It assesses several cognitive domains and can be administered
in approximately 10 min. The patient’s baseline MoCA score was
24 of a maximum 30, and the baseline MMSE was 23 of 30. In
both the MoCA and MMSE, the lower the score, the more cog-
nitively impaired the patient. The baseline FDG PET scan was
done using 18.1 mCi 18F-FDG. Blood glucose during testing was
107 mg/dL, DTST 45 min. At this time, there was relatively less
metabolic activity to the anterior temporal lobes and to the lateral
parietal lobes, right greater than left, than to the remainder of the
cortex (Figure 1A). Normal uptake was seen from the frontal and
occipital lobes and basal ganglia and cerebellum. The areas of rel-
ative hypometabolism, the anterior temporal, and parietal lobes,
supported the finding of probable Alzheimer type dementia. There
were no findings to support frontotemporal dementia. While not
conclusive, the neuropsychological testing and FDG PET images
were consistent with a diagnosis of probable AD. Since previous
studies had suggested that APOE4 non-carriers responded better
FIGURE 1 | 18-Fluorodeoxyglucose (18F) positron emission tomography
images. PET images were evaluated in conjunction with CT images for both
attenuation correction and anatomic fusion localization. Multiplanar PET
images were obtained and evaluated as part of this study. (A) Image taken
August 31st, 2012. Arrow indicates relative hypometabolism of right lateral
parietal lobe. (B) Image taken December 18th, 2012. Findings are stable from
the prior exam. Arrow indicates relative hypometabolism of right lateral
parietal lobe. The pattern of hypometabolism involving the parietal and
temporal lobes is stable and is consistent with the clinical diagnosis of
probable Alzheimer’s disease.
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to induced ketosis, the patient was screened for APOE4 carriage
status and was found to be an APOE4 non-carrier.
On the day after the Baseline evaluation, the patient was started
on CT following a graduated dosing schedule. The CT formula-
tion was provided in sachets containing a dry powder composed
of 50% CT. The graduated dosing schedule began with the patient
taking 10 g of material (5 g CT) for the first 2 days and then the
dose was increased by 10 g (5 g of CT) every 2 days, until after
7 days, the patient was consuming the full 40 g dose (20 g CT). For
the remaining 102 days, the CT formulation was administered at
40 g (20 g). The study was approved by the local Ethics Committee
(High Point Regional Health System Institutional Review Board,
IRB00003056). Written informed consent was obtained from the
patient for the study.
The patient remained on 40 g/day (20 g CT) dosing for 102 days.
On December 18th, 2012, the patient returned for cognitive eval-
uation (MoCA and MMSE) and underwent an FDG PET scan
(17.5 mCi 18F-FD, blood glucose during testing was 112 mg/dL,
DTST 45 min). The pattern of hypometabolism involving the pari-
etal and temporal lobes was noted to be stable when compared to
the prior exam (Figure 1B). The MoCA score changed from a
baseline value of 24 to a Day 109 value of 28. The MMSE score
changed from a Baseline value of 23 to a Day 109 value of 28
(Figure 2).
To evaluate the change in cognitive performance, we used a
Bayesian approach to compare the scores of the patient at Baseline
and at Day 109 to normative datasets of MMSE and MoCA scores
using the method of Crawford and Garthwaite (2007). For the
MoCA,normative scores for the patient’s age and education level of
27.4 (standard deviation, 2.2) were used (Nasreddine et al., 2005)
and for MMSE, 28 (standard deviation, 1.6) were used (Crum et al.,
1993) to calculate the Bayesian p-values for the patient’s scores,
FIGURE 2 | Change in MMSE and MoCA after 109days. Baseline values
are shown as shaded columns. Day 109 values are shown as open
columns. Baseline values were obtained on August 31st, 2012. The day
after the Baseline evaluation, the patient started on CT using a graduated
dosing schedule for 7 days, and for the remaining 102 days was dosed at
40 g (20 g of CT). Day 109 values were obtained on December 18th, 2012.
relative to the normal distribution using the program SINGLE-
BAYES.EXE1. At Baseline, the patient was significantly different
from the normal score for his age and education level on the
MMSE test (p= 0.002) but not the MoCA (p= 0.13). At Day 109,
the patient was well within the normal range of both the MMSE
(p= 0.99) and MoCA (p= 0.79) (see Table 1).
DISCUSSION
In this open label study, CT seems to have some ability to modu-
late cognitive performance as measured by the MoCA and MMSE
scores. This is consistent with previous studies, which showed
improvement in ADAS-Cog scores among APOE4 non-carriers
administered CT (Reger et al., 2004; Henderson et al., 2009). The
ADAS-Cog test is commonly used in clinical trials testing new
therapeutics for AD. However, the ADAS-Cog test is labor inten-
sive and can take 45–60 min to administer (Rosen et al., 1984).
Because of these reasons, the ADAS-Cog test is not commonly
used in clinical practice. In practice, it is more practical to moni-
tor patient outcomes with the use a rapid test such as the MoCA
or the MMSE. The MoCA test is readily available and has been
validated as a sensitive test of cognition in AD2. The present study
is the first report of the use of the MoCA test with CT and suggests
that the MoCA is an attractive measure of patient response.
Over the 109 day course of the study, the patient’s MoCA
increased by four points and the MMSE increased by five points.
This is in contrast to average changes in MMSE score reported
by 12 week, double-blind studies in AD. In a meta-analysis of the
effectiveness of medications for AD, little if any change in MMSE
can be detected over 12 weeks (Bond et al., 2012). Since the patient
described in the present study was not taking medications for AD,
they can best be compared to a naïve placebo population. In stud-
ies of similar length (12 weeks), average changes in MMSE score in
such populations range from 0.0 (n= 263) (Courtney et al., 2004)
to 1.8 (n= 55) (Holmes et al., 2004). This is consistent with the
finding that the patient was significantly different from the normal
MMSE score at Baseline using the Bayesian approach. However,
using this approach the MoCA score at Baseline did not yield a sig-
nificant difference from the normative data set. This is likely due to
the larger standard deviation in the MoCA normative data, com-
pared to the MMSE. Yet, due to variability in the disease state and
cognitive testing, the results of a single patient cannot be reliably
compared to larger clinical trials.
In addition, other factors may have influenced the outcome of
this study. For example, the patient was given CT as part of an
open label design and hence, changes in cognitive performance
may have been due to a placebo effect. Placebo effects have been
documented in AD trials using placebo-controlled designs (Ito
et al., 2013). Also, effects of mood, and in particular depression,
have been implicated in altering scores on the MMSE test (McCall
and Dunn, 2003). Therefore, the change in MMSE and MoCA
scores in a case study are at best suggestive and warrant further
confirmation in a larger more comprehensive study design.
The prior studies of the effects of CT in mild to moderate AD
did not examine changes in cerebral glucose metabolism during
1http://homepages.abdn.ac.uk/j.crawford/pages/dept/BayesSingleCase.htm
2http://www.mocatest.org
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Table 1 | Outcomes.
Test Normative data Baseline Bayesian Day 109 Bayesian
Mean (SD) Patient score p-Value Score patient p-Value
MMSE 28 (1.6) (Crum et al., 1993) 23 0.002 28 0.99
MoCA 27.4 (2.2) (Nasreddine et al., 2005) 24 0.13 28 0.79
the induction of ketosis. Such changes might be anticipated based
on the proposed mechanism of action. Previous studies had sug-
gested that infusion of ketone bodies would significantly alter the
CMRglc metabolism. Infusion of BHB to approximately 2 mM
reduces cerebral glucose metabolism by 30% (Hasselbalch et al.,
1996). The present study is the first report of an attempt to measure
changes in CMRglc with CT induced ketosis and may aid in the
design and development of future studies. The obvious limitation
of these observations is that they are derived from a single-case
report.
The FDG PET images presented here indicate no observable
changes in glucose uptake in any region of the brain. The level of
ketone bodies produced by CT therapy is in the range of 0.4 mM
(Henderson et al., 2009), much lower than the previously reported
infusion levels. This would represent approximately 3–5% of total
brain metabolism (Cunnane et al., 2011). Such a minor contri-
bution to cerebral metabolism may not be detectable in the FDG
PET scan reported here. This is an important observation for the
design of future FDG PET studies in which mild ketosis is induced.
Alternatively, the failure to modify brain glucose metabolism
may point to a different mechanism of action attributed to ketone
bodies that are mediating changes in cognitive performance. For
example, as well as being a fuel source, ketone bodies also act
as signaling metabolites. The major ketone body BHB has been
identified as an inhibitor of type I histone de-acetylases (HDAC).
Inhibition of this class of HDAC by BHB has been associated with
a variety of protective measures such as stress resistance, longevity,
and metabolic health [for review see Newman and Verdin (2014)].
Thus, the changes in gene expression by modification of HDAC
and other protein targets may be responsible for the increased
MoCA and MMSE scores in the present study.
CONCLUDING REMARKS
In conclusion, this is the first report of the use of 18FDG PET
and the MoCA test in a patient administered CT for 109 days. The
results suggest that CT may have an effect on cognitive function
in mild AD, though glucose uptake and metabolism may remain
unchanged. This finding may suggest that ketone bodies are not
simply acting as an energy source, but may be working to modify
gene expression through changing HDAC activity. However, due
to the low level of reported ketosis and the inherent variability in
the disease state and cognitive testing, the results of a single patient
must be viewed in the context of a case study, and further studies
are warranted.
REFERENCES
Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., et al. (2012).
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine
and memantine for the treatment of Alzheimer’s disease (review of technology
appraisal no. 111): a systematic review and economic model. Health Technol.
Assess. 16, 1–470. doi:10.3310/hta16210
Courtney,C.,Farrell,D.,Gray,R.,Hills,R.,Lynch,L.,Sellwood,E., et al. (2004). Long-
term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000):
randomised double-blind trial. Lancet 363, 2105–2115. doi:10.1016/S0140-
6736(04)16499-4
Crawford, J. R., and Garthwaite, P. H. (2007). Comparison of a single case to a
control or normative sample in neuropsychology: development of a Bayesian
approach. Cogn. Neuropsychol. 24, 343–372. doi:10.1080/02643290701290146
Crum, R. M., Anthony, J. C., Bassett, S. S., and Folstein, M. F. (1993). Population-
based norms for the mini-mental state examination by age and educational level.
JAMA 269, 2386–2391. doi:10.1001/jama.269.18.2386
Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S.,
et al. (2011). Brain fuel metabolism, aging, and Alzheimer’s disease. Nutrition
27, 3–20. doi:10.1016/j.nut.2010.07.021
de Leon, M. J., Ferris, S. H., George, A. E., Christman, D. R., Fowler, J. S., Gentes,
C., et al. (1983). Positron emission tomographic studies of aging and Alzheimer
disease. AJNR Am. J. Neuroradiol. 4, 568–571.
Freeman, J., Veggiotti, P., Lanzi, G., Tagliabue, A., and Perucca, E. (2006). The
ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res. 68,
145–180. doi:10.1016/j.eplepsyres.2005.10.003
Hasselbalch, S. G., Madsen, P. L., Hageman, L. P., Olsen, K. S., Justesen, N., Holm,
S., et al. (1996). Changes in cerebral blood flow and carbohydrate metabolism
during acute hyperketonemia. Am. J. Physiol. 270, E746–E751.
Henderson, S. T., Vogel, J. L., Barr, L. J., Garvin, F., Jones, J. J., and Costantini, L. C.
(2009). Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s
disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr.
Metab. (Lond.) 6, 31. doi:10.1186/1743-7075-6-31
Holmes, C., Wilkinson, D., Dean, C., Vethanayagam, S., Olivieri, S., Langley, A., et al.
(2004). The efficacy of donepezil in the treatment of neuropsychiatric symptoms
in Alzheimer disease. Neurology 63, 214–219. doi:10.1212/01.WNL.0000129990.
32253.7B
Ito, K., Corrigan, B., Romero, K., Anziano, R., Neville, J., Stephenson, D., et al.
(2013). Understanding placebo responses in Alzheimer’s disease clinical tri-
als from the literature meta-data and CAMD database. J. Alzheimers Dis. 37,
173–183. doi:10.3233/JAD-130575
McCall, W. V., and Dunn, A. G. (2003). Cognitive deficits are associated with func-
tional impairment in severely depressed patients. Psychiatry Res. 121, 179–184.
doi:10.1016/j.psychres.2003.09.003
Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., et al. (2009).
FDG-PET changes in brain glucose metabolism from normal cognition to patho-
logically verified Alzheimer’s disease.Eur. J.Nucl.Med.Mol. Imaging 36,811–822.
doi:10.1007/s00259-008-1039-z
Nasreddine, Z. S., Phillips, N. A., Bedirian, V., Charbonneau, S., Whitehead, V.,
Collin, I., et al. (2005). The Montreal cognitive assessment, MoCA: a brief
screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695–699.
doi:10.1111/j.1532-5415.2005.53221.x
Newman, J. C., and Verdin, E. (2014). Ketone bodies as signaling metabolites.Trends
Endocrinol. Metab. 25, 42–52. doi:10.1016/j.tem.2013.09.002
Owen, O. E., Morgan, A. P., Kemp, H. G., Sullivan, J. M., Herrera, M. G., and Cahill,
G. F. Jr. (1967). Brain metabolism during fasting. J. Clin. Invest. 46, 1589–1595.
doi:10.1172/JCI105650
Padilla, C., and Isaacson, R. S. (2011). Genetics of dementia. Continuum (Minneap.
Minn.) 17, 326–342. doi:10.1212/01.CON.0000396965.20811.df
Reger, M. A., Henderson, S. T., Hale, C., Cholerton, B., Baker, L. D., Watson, G. S.,
et al. (2004). Effects of beta-hydroxybutyrate on cognition in memory-impaired
adults. Neurobiol. Aging 25, 311–314. doi:10.1016/S0197-4580(03)00087-3
Rosen, W. G., Mohs, R. C., and Davis, K. L. (1984). A new rating scale for Alzheimer’s
disease. Am. J. Psychiatry 141, 1356–1364.
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 133 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Farah Caprylic triglyceride in Alzheimer’s disease
Schellenberg, G. D., and Montine, T. J. (2012). The genetics and neuropathology of
Alzheimer’s disease. Acta Neuropathol. 124, 305–323. doi:10.1007/s00401-012-
0996-2
Conflict of Interest Statement: The author of this manuscript is a paid consultant
of Accera Inc. Accera develops and has commercialized Medium Chain Triglcyeride
based medical food for mild to moderate Alzhiemer’s disease.
Received: 13 September 2013; paper pending published: 18 October 2013; accepted: 06
June 2014; published online: 16 July 2014.
Citation: Farah BA (2014) Effects of caprylic triglyceride on cognitive performance
and cerebral glucose metabolism in mild Alzheimer’s disease: a single-case observation.
Front. Aging Neurosci. 6:133. doi: 10.3389/fnagi.2014.00133
This article was submitted to the journal Frontiers in Aging Neuroscience.
Copyright © 2014 Farah. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 133 | 5
